Onabotulinum Toxin A in Direct Brow Lift

NAActive, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Direct Brow LiftScarring
Interventions
DRUG

Botox Injectable Product

The side randomized to receive treatment will be injected with onabotulinum toxin A. Wound healing, scar characteristics, and patient satisfaction will be assessed post operatively. Scarring will be assessed by the patient, medical observers and a lay observer, all masked to the treatment vs placebo side. Standardized scales will be used, and pre-operative, intra-operative, and post-operative photographs will be taken for all participants. ImageJ software will be used to analyze the photos and measure the degree of brow lift achieved on each side, to ensure this has not been affected by onabotulinum toxin injection.

OTHER

No intervention (placebo)

This group (of brows) will be receiving placebo injections containing normal saline. They will be assessed in the same manner as the treatment side.

Trial Locations (1)

B3H 2Y9

Eye Care Centre, Victoria General Hospital, Halifax

All Listed Sponsors
collaborator

Dalhousie University

OTHER

lead

Nova Scotia Health Authority

OTHER